2'-fluoro-5-ethylarabinosyluracil

DB13030InvestigationalSmall molecule

2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma, and Recurrent Mantle Cell Lymphoma,...

Mechanism: Pharmacologically active on Thymidylate synthase and Thymidine kinase, cytosolic
Curator reviewed
Formula / weight: C₉H₁₁FN₂O₅ · 246.194 g/mol (avg)

Resolves to

Compound

UNIIK7386OMP29CAS69123-94-0ChEMBLCHEMBL3228489PubChem3007908

Structure

InChIKeyUIYWFOZZIZEEKJ-PXBUCIJWSA-NSMILESOC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N1C=CC(=O)NC1=O

Targets

P04818TYMSP04183TK1

What you can answer from here — as of July 27, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with 2'-fluoro-5-ethylarabinosyluracil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account